1. Home
  2. XWEL vs PULM Comparison

XWEL vs PULM Comparison

Compare XWEL & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XWEL

XWELL Inc.

HOLD

Current Price

$1.16

Market Cap

9.0M

ML Signal

HOLD

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$1.24

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XWEL
PULM
Founded
2006
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
9.4M
IPO Year
2010
2013

Fundamental Metrics

Financial Performance
Metric
XWEL
PULM
Price
$1.16
$1.24
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
187.9K
32.9K
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
46.18
EPS
N/A
N/A
Revenue
$29,210,000.00
$7,910,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5069.93
52 Week Low
$0.26
$1.16
52 Week High
$2.20
$9.37

Technical Indicators

Market Signals
Indicator
XWEL
PULM
Relative Strength Index (RSI) 48.81 34.83
Support Level $1.01 $1.18
Resistance Level $1.26 $1.46
Average True Range (ATR) 0.08 0.10
MACD -0.01 0.04
Stochastic Oscillator 56.00 26.67

Price Performance

Historical Comparison
XWEL
PULM

About XWEL XWELL Inc.

XWELL Inc is an international wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa, XpresTest, and Naples Wax Center. The XpresSpa segment, which generates maximum revenue, operates spa service locations in airports, offering massage, skincare, and travel products. The XpresTest segment provides aircraft wastewater and passenger nasal sampling through the CDC's bio-surveillance program. The Naples Wax Center segment operates six locations offering face and body waxing, skincare services, and cosmetic products. The Company generates maximum revenue from the United States.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: